Abiopharma

🔍 Pollock Frederick (Executive)

Company: GCM Grosvenor Inc. (GCMG)

Report Date: 2026-05-31

Detailed Transactions and Holdings:

• Acquired 25,000 shares of Class A Common Stock (Direct)
  Date: 2026-05-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 786,110.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 9,838 shares of Class A Common Stock at $10.63 per share (Direct)
  Date: 2026-05-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 776,272.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 25,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F1

Footnotes:

• F1: Represents restricted stock units ("RSUs") that were granted under the Issuer's 2020 Incentive Award Plan on March 1, 2023. 25,000 RSUs vested on May 31, 2024, 25,000 RSUs vested on May 31, 2025 and 25,000 RSUs vested on May 31, 2026. 25,000 shares of Class A Common Stock of the Issuer were delivered to the Reporting Person in settlement of 25,000 vested RSUs on May 31, 2026.
• F2: Each RSU represents the contingent right to receive one share of Class A Common Stock of the Issuer.
• F3: Represents shares of Class A Common Stock that have been withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of RSUs that vested on May 31, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.